Skip to main content

Peer Review reports

From: Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab

Original Submission
23 Mar 2021 Submitted Original manuscript
23 Apr 2021 Reviewed Reviewer Report - Julie Lemieux Lemieux
3 May 2021 Reviewed Reviewer Report
4 Jun 2021 Author responded Author comments - Zahi Mitri
Resubmission - Version 2
4 Jun 2021 Submitted Manuscript version 2
9 Jun 2021 Author responded Author comments - Zahi Mitri
Resubmission - Version 3
9 Jun 2021 Submitted Manuscript version 3
Publishing
13 Oct 2021 Editorially accepted
27 Oct 2021 Article published 10.1186/s12885-021-08894-2

You can find further information about peer review here.

Back to article page